

US010941173B2

(12) United States Patent Lu et al.

(54) RHAMNOLIPID AMIDES FOR HAIR SCENT RETENTION

(71) Applicant: **Evonik Operations GmbH**, Essen (DE)

(72) Inventors: Xin Lu, Essen (DE); Sandra Nattland, Essen (DE); Monica Desiree van Logchem, Zevenberger (NL); Hans Henning Wenk, Mülheim an der Ruhr (DE); Fabien Cabirol, Paris (FR); Verena Dahl, Bergisch Gladbach (DE); Ralph Scheuermann, Bottrop (DE); Kathrin Daniela Brandt, Düsseldorf

(73) Assignee: Evonik Operations GmbH, Essen

(DE)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

(DE); Jochen Kleinen, Heinsbert (DE)

U.S.C. 154(b) by 167 days.

(21) Appl. No.: 16/074,828

(22) PCT Filed: Feb. 15, 2017

(86) PCT No.: PCT/EP2017/053349

§ 371 (c)(1),

(2) Date: Aug. 2, 2018

(87) PCT Pub. No.: **WO2017/144318**

PCT Pub. Date: Aug. 31, 2017

(65) Prior Publication Data

US 2019/0040095 A1 Feb. 7, 2019

(30) Foreign Application Priority Data

(51) Int. Cl. C07H 15/06 (2006.01) C07H 15/04 (2006.01) A61K 8/60 (2006.01) C07H 1/00 (2006.01) A61Q 5/02 (2006.01) A61Q 13/00 (2006.01)

(10) Patent No.: US 10,941,173 B2

(45) **Date of Patent:** Mar. 9, 2021

(58) Field of Classification Search

None

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

6,020,526	A *	2/2000	Schwartz A61K 9/1272
			562/561
9,243,212	B2	1/2016	Kuppert et al.
9,434,755	B2	9/2016	Schilling et al.
2014/0296168	A1	10/2014	Schilling et al.
2017/0306264	A 1	10/2017	Peggau et al.
2017/0335238	A 1	11/2017	Schilling et al.
2018/0016525	A 1		Scheuermann et al.
2018/0023040	A 1	1/2018	Schilling et al.
2019/0127411	A1*	5/2019	Kerr C12N 15/52

FOREIGN PATENT DOCUMENTS

EP	2786742 A1	8/2014
WO	2017144317 A1	8/2017
WO	2017144318 A1	8/2017

OTHER PUBLICATIONS

Chen et al., "Rhizoleucinoside, a Rhamnolipid-Amino Alcohol Hybrid from the Rhizobial Symbiont *Bradyrhizobium* sp. BTAi1" Organic Letters vol. 18 pp. 1490-1493 (Year: 2016).*

Johnston et al., "Nonribosomal Assembly of Natural Lipocyclocarbamate Lipoprotein-Associated Phospholipase Inhibitors" ChemBioChem vol. 14 pp. 431-435 (Year: 2013).*

Nakajima et al., "Mechanism of Amide Formation by Carbodiimide for Bioconjugation in Aqueous Media" Bioconjugate Chem vol. 6 pp. 123-130 (Year: 1995).*

Thirkettle J. et al; SB-253514 and Analogues; Novel Inhibitors of Lipoprotein-Associated Phospholipase A; The Journal of Antibiotics; vol. 53 No. 7, Jul. 1, 2000, pp. 664-669.

Schmidt Y. et al; Biosynthetic Origin of the Antibiotic Cyclocarbamate Brabantamide A in Plant-Associated Pseudomonas; ChemBioChem Jan. 16, 2014, 15; pp. 259-266.

Miao, S. et al; Ethylation of Di-rhamnolipids: A Green Route to Produce Novel Sugar Fatty Acid Nonionic Surfactants; J Surfact Deterg (Sep. 11, 2014) 17; pp. 1069-1080.

Westerduin P. et al; Synthesis of Methyl 3-[3-(2-0-cx-L-Rhamnopyranosyl-pt-L-Rham-Nopyranosyloxy) Decanoyloxy] Decanoate, A Rhamnolipid from Pseudomonas Aeruginosa; Carbohydrate Research, 180 (Sep. 15, 1988) pp. 195-205.

* cited by examiner

(2013.01)

Primary Examiner — Eric Olson (74) Attorney, Agent, or Firm — Taylor English Duma LLP; Philip P. McCann

(57) ABSTRACT

The invention provides derivatives of rhamnolipids, formulations comprising these, and the use thereof.

19 Claims, No Drawings

RHAMNOLIPID AMIDES FOR HAIR SCENT RETENTION

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a 35 U.S.C. § 371 U.S. national phase entry of International Application No. PCT/EP201.7/053349 having an international filing date of Feb. 15, 2017, which claims the benefit of European Application No. 16156664.1 filed Feb. 22, 2016, each of which is incorporated herein by reference in its entirety.

FIELD

The invention provides derivatives of rhamnolipids, formulations comprising these, and the use thereof.

BACKGROUND

Rhamnolipids are surfactants which can be prepared by ²⁰ means of fermentation. They are composed of one to two rhamnose units and one to three, mostly β-hydroxy fatty acids. The fatty acids can be saturated or unsaturated. The variation in the chain length and amount (congeners) of the fatty acid fractions has been described in a number of ²⁵ publications. (Howe et al., FEBS J. 2006; 273(22):5101-12; Abdel-Mawgoud et al., Appl Microbiol Biotechnol, 86, 2010; pp. 1323-1336). A few covalent derivatives of the fatty acid fractions of rhamnolipids are known. There are primarily a number of rhamnolipid esters described in the ³⁰ literature. Hirayama et al., FEBS Letters, Volume 139, Issue 1, 1982; Pages 81-85, describes the identification of rhamnolipid methyl esters in liquid cultures of *Pseudomonas* aeruginosa. Miao et al., Journal of Surfactants and Detergents, 17 (6), 2014; 1069-1080, describes the synthesis of ³⁵ di-rhamnolipid ethyl esters by the esterification with ethanol.

SUMMARY

It was an object of the invention to provide substances which make it possible for a surface, in particular that of hair, to have a scent for as long as possible.

DETAILED DESCRIPTION

Surprisingly, it has been found that the rhamnolipid amides described below are able to achieve the set object of the invention.

The present invention therefore provides rhamnolipid 50 amides and salts thereof.

The invention further provides a process for the preparation of the rhamnolipid amides according to the invention, and the use thereof.

One advantage of the present invention is that, following 55 H. treatments with the formulations according to the invention, the hair has a significantly better fragrance retention.

A further advantage of the present invention is that the compositions according to the invention bestow a beautiful shine upon the hair.

A yet further advantage is that the compositions according to the invention are able to improve the combability and shapeability of hair.

A yet further advantage is that the preparation process is very mild and gentle, meaning that the desired sugar struc- 65 ture is not destroyed, but an esterification is nevertheless possible.

2

A further advantage is that the product can be isolated and worked up in an excellent manner.

The terms "rhamnolipid" and "rhamnolipid amide" in connection with the present invention also always include their corresponding salts.

The term "rhamnolipid amide" in connection with the present invention is understood as meaning in particular compounds of the general formula (I),

formula (I)

where

m=2, 1 or 0, in particular 1 or 0, n=1 or 0, in particular 1,

R¹=organic radical having 2 to 24, preferably 5 to 13, carbon atoms, in particular optionally branched, optionally substituted, in particular hydroxy-substituted, optionally unsaturated, in particular optionally mono-, bi- or tri-unsaturated, alkyl radical, preferably one selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and (CH₂)_o—CH₃ where o=1 to 23, preferably 4 to 12,

R²=independently of one another, identical or different, organic radical having 2 to 24, preferably 5 to 13, carbon atoms, in particular optionally branched, optionally substituted, in particular hydroxy-substituted, optionally unsaturated, in particular optionally mono-, bi- or tri-unsaturated, alkyl radical, preferably one selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and (CH₂)_o—CH₃ where o=1 to 23, preferably 4 to 12,

 R^{3a} =organic radical with 2 to 24, preferably 3 to 13, particularly preferably 4 to 8 carbon atoms,

and R^{3b}=organic radical with 2 to 24, preferably 3 to 13, particularly preferably 4 to 8, carbon atoms or H, preferably H.

In accordance with the invention, the organic radicals R^{3a} and R^{3b} are preferably selected from optionally mono- or polyunsaturated alkyl radicals, which optionally have at least one amine group.

The term "mono-rhamnolipid" in connection with the present invention is understood as meaning compounds of the general formula (I) where $-NR^{3a}R^{3b}$ =-OH or salts thereof, in which n=0.

Distinct rhamnolipids are abbreviated according to the following nomenclature:

"diRL-CXCY" is understood as meaning di-rhamnolipids of the general formula (I) where —NR^{3a}R^{3b}=—OH or salts

thereof, in which one of the radicals R^1 and $R^2=(CH_2)_o$ — CH_3 where o=X-4 and the remaining radical R^1 or $R^2=(CH_2)_o$ — CH_3 where o=Y-4.

"monoRL-CXCY" is understood as meaning mono-rhamnolipids of the general formula (I) where — $NR^{3a}R^{3b}$ =—OH or salts thereof, in which one of the radicals R^1 and R^2 = $(CH_2)_o$ — CH_3 where o=X-4 and the remaining radical R^1 or R^2 = $(CH_2)_o$ — CH_3 where o=Y-4. The nomenclature used therefore does not differ between "CXCY" and "CYCX".

For rhamnolipids where m=0, monoRL-CX or diRL-CX is used accordingly.

If one of the abovementioned indices X and/or Y is provided with ":Z", this signifies that the respective radical R¹ and/or R²=an unbranched, unsubstituted hydrocarbon radical having X-3 or Y-3 carbon atoms having Z double bonds.

Analogous nomenclature is used for rhamnolipid amides in the form di/monoRL-CXCY:Z amide.

The "pH" in connection with the present invention is defined as the value which is measured for the corresponding substance at 25° C. after stirring for 5 minutes using a 20 pH electrode calibrated in accordance with ISO 4319 (1977).

Unless stated otherwise, all percentages (%) given are percentages by mass.

Preferred rhamnolipid amides are selected from compounds of the general formula (I), where

m=2, 1 or 0, particularly 1 or 0,

n=1 or 0, particularly 1,

R¹=optionally branched, optionally substituted, in particular hydroxy-substituted, optionally unsaturated, in particular, optionally mono, di- or triunsaturated alkyl radical having 2 to 24, preferably 5 to 13 carbon atoms, preferably those selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and (CH₂)_o—CH₃ where o=1 to 23, preferably 4 to 12,

R²=optionally branched, optionally substituted, in particular hydroxy-substituted, optionally unsaturated, in particular, optionally mono-, di- or triunsaturated alkyl radical having 2 to 24, preferably 5 to 13 carbon atoms, preferably those selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and (CH₂)_o—CH₃, where o=1 to 23, preferably 4 to 12.

Particularly preferred rhamnolipid amides are selected from diRLC10C10 amides, diC8C10 amides, diRLC10C12 amides, diRLC10C12:1 amides and monoRLC10C10 amides where R³a=organic radical having 2 to 24, preferably 3 to 13, particularly preferably 4 to 8 carbon atoms, and preferably R³b=H.

Likewise particularly preferred rhamnolipid amides are characterized in that R^{3a} is selected from the group of the alkyl radicals having 2 to 24, preferably 3 to 13, particularly preferably 4 to 8 carbon atoms, which optionally have at least one amine group, in particular having 4 to 8 carbon atoms, and preferably R^{3b}=H. In this connection, in particular rhamnolipid amides are preferably selected from diRLC10C10 amides, diC8C10 amides, diRLC10C12 amides, diRLC10C12:1 amides and monoRLC10C10 55 amides.

Very particularly preferred rhamnolipid amides are characterized in that R^{3a} is selected from the group comprising preferably consisting of

$$-R^6-N$$

$$R^5$$

4

where

R⁴ and R⁵=independently of one another, identical or different alkyl radical having 1 to 6, preferably 1 to 3, particularly preferably 1, carbon atoms,

R⁶=an alkylene group having 1 to 6, preferably 2 to 3, carbon atoms,

and

$$--R^7$$

where

R⁷=an alkylene group having 1 to 22, preferably 2 to 18, in particular 3 to 8, carbon atoms,

Z=H, OH, OR⁸ where

R⁸=alkyl radical having 1 to 6, preferably 1 to 3, particularly preferably 1, carbon atoms, and preferably R^{3b}=H.

In this connection, in particular rhamnolipid amides are preferably selected from diRLC10C10 amides, diC8C10, diRLC10C12 amides, diRLC10C12:1 amides and mono RLC10C10 amides.

In an alternative, preferred embodiment, the rhamnolipid amides according to the invention are characterized in that the radical —NR^{3a}R^{3b} is derived from an amine NHR^{3a}R^{3b} selected from amino acids and peptides. Amino acids preferred in this connection are selected from the proteinogenic amino acids. Furthermore, peptides preferred in this connection are selected from peptides which consist of proteinogenic amino acids, in particular those peptides comprising 2 to 20, in particular 4 to 16, very particularly preferably 4 to 8, amino acids

The rhamnolipid amides according to the invention are preferably mixture compositions of rhamnolipid amides which are characterized in particular in that they contain mono- and di-rhamnolipid amides.

Depending on the application, it may be preferred that the
mixture compositions according to the invention comprise
more percent by weight of mono-rhamnolipid amides than
di-rhamnolipid amides or more percent by weight of dirhamnolipid amides than mono-rhamnolipid amides, where
the percentages by weight refer to all of the mono- and
di-rhamnolipid amides present in the mixture composition.

Thus, for example, the mixture compositions according to the invention can comprise, for example, more than 60% by weight, in particular more than 80% by weight, or even more than 95% by weight, of di-rhamnolipid amides, or else also for example more than 60% by weight, in particular more than 80% by weight, or even more than 95% by weight, of mono-rhamnolipid amides, where the percentages by weight refer to all of the mono- and di-rhamnolipid amides present in the mixture composition.

The present invention further provides a process for the preparation of rhamnolipid amides comprising the process steps

A) provision of at least one rhamnolipid,

B) reaction of the rhamnolipid with at least one coupling reagent,

C) reaction of the rhamnolipid activated by process step B) with an amine, and optionally

D) purification of the rhamnolipid amide.

Process step A) is carried out according to the generally known processes of the prior art, in particular using genetically modified microorganisms which preferably overexpress rhamnolipid synthesis genes, these genes preferably

being selected from rhlA, rhlB and rhlC. Corresponding instructions can be found by the person skilled in the art in e.g. US2014296168 and WO2012013554.

It is preferred according to the invention that in process step B) the coupling reagent used is at least one selected 5 from the group comprising, preferably consisting of, dicyclohexylcarbodiimide, diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-cyclohexyl-N'-(2'-morpholinoethyl)carbodiimide methop-toluenesulphonate, N-benzyl-N'-3' dimethylaminopropyl- 10 carbodiimide hydrochloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, N-ethylcarbodiimide hydrochloride and carbonyldiimidazole, particularly preferably dicyclohexylcarbodiimide and diisopropylcarbodiimide.

Likewise, it is preferred according to the invention that in process step C) at least one catalyst selected from the group comprising, preferably consisting of, N-ethyldiisopropylamine, trialkylamines, pyridine, 4-dimethylaminopyridine and hydroxybenzotriazole, in particular hydroxybenzotriazole, is used.

Processes preferred according to the invention preferably lead to the rhamnolipid amides referred to above as preferred according to the invention.

Thus, for example preferably in process step A) preferably rhamnolipids selected from diRLC10C10, diC8C10, diRLC10C12, diRLC10C12:1 and monoRLC10C10 or mixtures thereof are used. Accordingly, preference is given to the use of amines in process step C)

$$R^4$$
 R^6
 R^5

selected from the group where

R⁴ and R⁵=independently of one another, identical or different alkyl radical having 1 to 6, preferably 1 to 3, particularly preferably 1, carbon atoms,

R⁶=an alkylene group having 1 to 6, preferably 2 to 3, carbon atoms,

and

$$H_2N-R^7$$

where

in particular 3 to 8, carbon atoms,

Z=H, OH, OR⁸ where

R⁸=alkyl radical having 1 to 6, preferably 1 to 3, particularly preferably 1, carbon atoms.

of amines in process step C) selected from amino acids and peptides. Amino acids preferred in this connection are selected from the proteinogenic amino acids. Furthermore, peptides preferred in this connection are selected from peptides which consist of proteinogenic amino acids, in 60 nonionic surfactants in which EO and PO units are not particular those peptides comprising 2 to 20, in particular 4 to 16, very particularly preferably 4 to 8, amino acids.

The invention further provides the rhamnolipid amides obtainable by the process according to the invention.

The rhamnolipid amides according to the invention can 65 are also alkyl glycosides. advantageously be incorporated into in particular cosmetic formulations.

Consequently, the present invention further provides the use of the rhamnolipid amides according to the invention for producing formulations, in particular cosmetic formulations,

and the formulations, in particular cosmetic formulations, which comprise the rhamnolipid amides according to the invention.

The formulations according to the invention are preferably aqueous formulations.

The term "aqueous formulation" in connection with the present invention is to be understood as meaning a formulation which comprises at least 5% by weight of water, based on the overall composition under consideration.

According to the invention, it is preferred if the formu-15 lations according to the invention comprise the rhamnolipid amides according to the invention in an amount of from 0.05% by weight to 40% by weight, preferably from 0.2% by weight to 20% by weight, particularly preferably from 0.5% by weight to 12% by weight, where the percentages by 20 weight refer to the total formulation.

Preferred formulations according to the invention comprise, in addition to the rhamnolipid amides according to the invention, at least one further surfactant, it being possible to use, for example, anionic, nonionic, cationic and/or amphoteric surfactants. From an applications point of view, preference is given to mixtures of anionic and nonionic surfactants. The total surfactant content of the aqueous formulation is preferably 5 to 60% by weight and particularly preferably 15 to 40% by weight, based on the total formulation. The 30 nonionic surfactants used are preferably alkoxylated, advantageously ethoxylated, in particular primary alcohols having preferably 8 to 18 carbon atoms and on average 1 to 12 mol of ethylene oxide (EO) per mole of alcohol, in which the alcohol radical can be linear or preferably 2-methyl-35 branched or can comprise linear and methyl-branched radicals in a mixture, as are usually present in oxo alcohol radicals. Of particular preference, however, are alcohol ethoxylates with linear radicals from alcohols of native origin having 12 to 18 carbon atoms, for example from 40 coconut, palm, tallow fatty or oleyl alcohol, and on average 2 to 8 EO per mole of alcohol. The preferred ethoxylated alcohols include for example C12-C14-alcohols having 3 EO, 4 EO or 7 EO, C9-C11-alcohol with 7 EO, C13-C15alcohols with 3 EO, 5 EO, 7 EO or 8 EO, C12-C18-alcohols 45 with 3 EO, 5 EO or 7 EO and mixtures of these, such as mixtures of C12-C14-alcohol with 3 EO and C12-C18alcohol with 7 EO. The stated degrees of ethoxylation are statistical average values which can be an integer or a fraction for a specific product. Preferred alcohol ethoxylates R^7 =an alkylene group having 1 to 22, preferably 2 to 18, 50 have a narrowed homologue distribution. In addition to these nonionic surfactants, it is also possible to use fatty alcohols with more than 12 EO. Examples thereof are tallow fatty alcohol with 14 EO, 25 EO, 30 EO or 40 EO. It is also possible to use nonionic surfactants which contain EO and Accordingly, preference is alternatively given to the use 55 PO (propylene oxide) groups together in the molecule. Here, it is possible to use block copolymers with EO-PO block units or PO-EO block units, but also EO-PO-EO copolymers or PO-EO-PO copolymers.

It is of course also possible to use mixed alkoxylated distibuted blockwise, but randomly. Such products are obtainable through the simultaneous action of ethylene oxide and propylene oxide on fatty alcohols.

Moreover, further nonionic surfactants that can be used

A further class of preferably used nonionic surfactants, which are used either as the sole nonionic surfactant or in

combination with other nonionic surfactants, are alkoxylated, preferably ethoxylated or ethoxylated and propoxylated fatty acid alkyl esters, preferably having 1 to 4 carbon atoms in the alkyl chain, in particular fatty acid methyl esters, as are described, for example, in the Japanese patent application JP 58/217598 or which are prepared preferably by the process described in the international patent application WO-A-90/13533.

Also nonionic surfactants of the amine oxide type, for example N-cocoalkyl-N,N-dimethylamine oxide and N-tallow-alkyl-N,N-dihydroxyethylamine oxide, and of the fatty acid alkanolamide type can be suitable. The amount of these nonionic surfactants is preferably not more than that of the thereof.

Further suitable surfactants are polyhydroxy fatty acid amides; polyhydroxy fatty acid amides are substances which can usually be obtained by reductive amination of a reducing sugar with ammonia, an alkylamine or an alkanolamine and 20 subsequent acylation with a fatty acid, a fatty acid alkyl ester or a fatty acid chloride.

Anionic surfactants that can be used are for example those of the sulphonate and sulphate types. Suitable surfactants of the sulphonate type here are preferably C9-C13-alkylbenzenesulphonates, olefinsulphonates, i.e. mixtures of alkeneand hydroxyalkanesulphonates and disulphonates, as are obtained for example from C12-C18-monoolefins with terminal or internal double bond by sulphonation with gaseous sulphur trioxide and subsequent alkaline or acidic hydrolysis 30 of the sulphonation products. Also of suitability are alkanesulphonates, which are obtained from C12-C18-alkanes for example by sulphochlorination or sulphoxidation with subsequent hydrolysis or neutralization.

Likewise of suitability are also the esters of α -sulpho fatty acids (ester sulphonates), for example the α -sulphonated methyl esters of the hydrogenated coconut, palm kernel or tallow fatty acids.

Further suitable anionic surfactants are sulphated fatty 40 acid glycerol esters. Fatty acid glycerol esters are to be understood as meaning the mono-, di- and triesters and mixtures thereof, as are obtained during the production by esterification of a monoglycerol with 1 to 3 mol of fatty acid or during the transesterification of triglycerides with 0.3 to 45 2 mol of glycerol. Preferred sulphated fatty acid glycerol esters here are the sulphation products of saturated fatty acids having 6 to 22 carbon atoms, for example of caproic acid, caprylic acid, capric acid, myristic acid, lauric acid, palmitic acid, stearic acid or behenic acid. Preferred alk(en) 50 yl sulphates are the alkali metal and in particular the sodium salts of the sulphuric acid half-esters of the C12-C18-fatty alcohols, for example from coconut fatty alcohol, tallow fatty alcohol, lauryl, myristyl, cetyl or stearyl alcohol or the C10-C20 oxo alcohols and those half-esters of secondary 55 alcohols of these chain lengths. Furthermore, preference is given to alk(en)yl sulphates of the stated chain length which contain a synthetic straight-chain alkyl radical produced on a petrochemical basis which have an analogous degradation behaviour to the equivalent compounds based on fatty 60 chemical raw materials. From a washing point of view, preference is given to the C12-C16-alkyl sulphates and C12-C18-alkyl sulphates and C14-C18-alkyl sulphates. Also 2,3-alkyl sulphates, which are prepared for example according to the U.S. Pat. No. 3,234,258 or 5,075,041 and can be 65 cosinate. obtained as commercial products of the Shell Oil Company under the name DAN®, are suitable anionic surfactants.

8

Also the sulphuric acid monoesters of the straight-chain or branched C7-C20-alcohols ethoxylated with 1 to 6 mol of ethylene oxide, such as 2-methyl-branched C9-C11-alcohols with on average 3.5 mol of ethylene oxide (EO) or C12-C18-fatty alcohols with 1 to 4 EO, are suitable. On account of their high foaming behaviour, they are used in cleaners only in relatively small amounts, for example in amounts of from 1 to 5% by weight. Further suitable anionic surfactants are also the salts of alkylsulphosuccinic acid, which are also referred to as sulphosuccinates or as sulphosuccinic acid esters and which are monoesters and/or diesters of sulphosuccinic acid with alcohols, preferably fatty alcohols and in particular ethoxylated fatty alcohols. Preferred sulphosucciethoxylated fatty alcohols, in particular not more than half 15 nates contain C8-C18 fatty alcohol radicals or mixtures thereof. Particularly preferred sulphosuccinates contain a fatty alcohol radical which is derived from ethoxylated fatty alcohols. In this case, sulphosuccinates whose fatty alcohol radicals are derived from ethoxylated fatty alcohols with a narrow homologue distribution are in turn particularly preferred. Likewise, it is also possible to use alk(en)ylsuccinic acid having preferably 8 to 18 carbon atoms in the alk(en)yl chain or salts thereof.

> Particularly preferred anionic surfactants are soaps. Saturated and unsaturated fatty acid soaps, such as the salts of lauric acid, myristic acid, palmitic acid, stearic acid, (hydrogenated) erucic acid and behenic acid and in particular soap mixtures derived from natural fatty acids, for example coconut, palm kernel, olive oil or tallow fatty acids.

The anionic surfactants including the soaps can be present in the form of their sodium, potassium or ammonium salts as well as soluble salts of organic bases, such as mono-, dior triethanolamine. Preferably, the anionic surfactants are present in the form of their sodium or potassium salts, in particular in the form of the sodium salts.

Amphoteric surfactants that can be used according to the invention are those surface-active compounds which carry in the molecule at least one quaternary ammonium group and at least one —COO⁻ or SO₃⁻ group. Particularly preferred amphoteric surfactants in this connection are betaine surfactants such as alkyl- or alkylamidopropylbetaines. In particular, betaines such as the N-alkyl-N,N-dimethylammoglycinates, e.g. cocoalkyldimethylammonium nium N-acylaminopropyl-N,N-dimethylammonium glycinate, glycinates, e.g. cocoacylaminopropyldimethylammonium glycinate, C12-C18-alkyldimethylacetobetaine, cocoamidopropyldimethylacetobetaine, 2-alkyl-3-carboxymethyl-3hydroxyethylimidazolines and sulphobetaines having in each case 8 to 18 carbon atoms in the alkyl or acyl group, and cocoacylaminoethyl hydroxyethyl carboxymethylglycinate are preferred here. A particularly preferred zwitterionic surfactant is the N,N-dimethyl-N-(lauroylamidopropyl)ammonium acetobetaine known under the INCI name Cocamidopropyl Betaine.

Further suitable amphoteric surfactants are the group of amphoacetates and amphodiacetates, in particular for example coco- or laurylamphoacetates or -diacetates, the group of the amphopropionates and amphodipropionates and the group of the amino acid-based surfactants such as acyl glutamates, in particular Disodium Cocoyl Glutamate and Sodium Cocoyl Glutamate, acyl glycinates, in particular Cocoyl Glycinate, and acyl sarcosinates, in particular Ammonium Lauroyl Sarcosinate and Sodium Cocoyl Sar-

The formulations according to the invention particularly preferably comprise a fragrance.

The formulations according to the invention can further comprise at least one additional component selected from the group of

emollients,

emulsifiers,

thickeners/viscosity regulators/stabilizers,

UV light protection filters,

antioxidants,

hydrotropes (or polyols),

solids and fillers,

film formers,

pearlescence additives,

deodorant and antiperspirant active ingredients,

insect repellents,

self-tanning agents,

preservatives,

conditioners,

dyes,

cosmetic active ingredients,

care additives,

superfatting agents,

solvents.

Substances which can be used as exemplary representatives of the individual groups are known to the person skilled in the art and can be found for example in the German application DE 102008001788.4. This patent application is herewith incorporated as reference and thus forms part of the disclosure.

As regards further optional components and the amounts used of these components, reference is made expressly to the relevant handbooks known to the person skilled in the art, for example K. Schrader, "Grundlagen and Rezepturen der Kosmetika [Fundamentals and principles of cosmetics]", 2nd edition, pages 329 to 341, Hüthig Buch Verlag Heidelberg.

The amounts of the particular additives are governed by the intended use.

Typical guide formulations for the respective applications are known prior art and are contained for example in the brochures of the manufacturers of the particular basic materials and active ingredients. These existing formulations can usually be adopted unchanged. If necessary, the desired 40 modifications can, however, be undertaken without complication by means of simple experiments for the purposes of adaptation and optimization.

The rhamnolipid amides according to the invention and the formulations according to the invention comprising the 45 rhamnolipid amides according to the invention can be used advantageously for cleaning surfaces. In this form of the use according to the information, the surface is preferably the surface of a living being, in particular of a human being, with surfaces of this type being particularly preferably 50 selected from skin and hair, in particular hair.

The present invention further provides the use of the rhamnolipid amides according to the invention and/or of the formulations according to the invention for fragrance retention, in particular on hair.

The examples listed below describe the present invention by way of example, without any intention of restricting the invention, the scope of application of which is apparent from the entirety of the description and the claims, to the embodiments specified in the examples.

EXAMPLES

Example 1: Preparation of Di-Rhamnolipids

A fermentation with a recombinant strain *Pseudomonas* putida KT2440S pBBR1MCS2-Plac-rhlABC-T-Ptac-rhlC-T

10

was carried out. The construction of the strain is described in US2014296168. The preculture in the shake flask was carried out as described in WO2012013554. For the main culture, a mineral medium (M9) was likewise used. The fermentation takes place in a glucose-limited fed-batch process in a 2 litre fermenter. The feeding in of glucose is regulated by reference to the dissolved-oxygen signal. The oxygen partial pressure of the fermentation broth was regulated at 20% saturation via the stirrer speed. The pH is regulated to 7 via a pH electrode and addition of 2M sulphuric acid or of a 20% by weight ammonia solution. In order to prevent excessive foaming of the fermentation broth, the antifoam DOW Corning 1500 was metered in as required. The fermentation was conducted over 4 days to a dry biomass of 15 g/l. The rhamnolipid concentration was determined by HPLC and was 9.8 g/l. After separating off the cells by means of centrifugation at 10 000 g, the fermentation broth was adjusted to a pH of 3.1 by adding concentrated H₂SO₄. Renewed centrifugation gave a pasty solid concentrate with an RL fraction of 45% by weight and with a viscosity of >10~000 mPas. With continuous stirring, a 50% strength by weight aqueous KOH solution was added to the pasty suspension of the concentrated rhamnolipid precipitate and a pH of 6 was established. The pasty mass liquefied at this point with an accompanying sharp drop in viscosity. The suspension gave rise to a clear solution. By adding water, the solution was adjusted to an active content of 35% by weight. The rhamnolipid purity was >90% by weight, based on the dry mass.

Rhamnolipid species verified by HPLC were:

	RL total [%] (HPLC)	91	
	diRL-C8C10	13.9	
5	monoRL-C8C10	0.51	
	diRL-C10C10	61.4	
	monoRL-C10C10	1.4	
	diRL-C10C12:1	5.9	
	diRL-C10C12	5.5	
	other RL	2.2	

Example 2: Preparation of Mono-Rhamnolipids

The 35% by weight rhamnolipid solution prepared as described above was diluted to 1% by adding water. Two litres of this solution were heated to 50° C. With gentle stirring, 200 units of a thermostable rhamnosidase (ThermoActiveTM Rhamnosidase A, Prokazyme) were added and the reaction was carried out overnight. After 20 h, a sample of the solution was analysed by means of HPLC. The di-rhamnolipid had been completely converted to monorhamnolipid and rhamnose. Then, the enzyme was deactivated for one hour at 80° C. The entire mixture was then freeze-dried. The freeze-dried product was adjusted to a mono-rhamnolipid active content of 35% by weight by adding water.

Example 3: Synthesis of Di-Rhamnolipid Dimethylamidopropylamide

60

To activate the acid function, 25 g of di-rhamnolipid with 6.25 ml of diisopropylcarbodiimide are dissolved in THF at 55° C. If the mixture achieves an acid number of <2, 5.36 ml of dimethylamidopropylamine are added, as is 1% by weight of 4-dimethylaminopyridine for the catalysis. Any unreacted coupling reagent should be deactivated beforehand by adding 2 ml of water. After a reaction time of 10 h, work-up is

carried out. The reaction mixture is dried on a rotary evaporator (45° C., <300 mbar); purification takes place by extracting through shaking with ethyl acetate (1):water (1) in two steps with 250 ml in each case. The rhamnolipid amide remains in the ethyl acetate phase. This is likewise dried on a rotary evaporator (45° C., <100 mbar), the di-rhamnolipid dimethylamidopropylamide remains as a solid.

Further purification of the product can take place by means of column chromatography. For this, Silica 60 Gel (SIGMA Aldrich) serves as stationary phase and ethyl acetate (99):water (1) with 1% acetic acid serves as mobile phase. Polar by-products or possible cleavage products are removed from a 5% strength solution of the di-rhamnolipid dimethylamidopropylamide crude product. For careful separation, a fraction comprises 10 ml at a dropping rate of 15 ml/min and for a total volume of 200 ml of starting solution.

Analytical determination by means of HPLC was carried out on a 50*3.0 mm column Poroshell 120 C18 (2.7 μm) in 20 mM NH₄ formate in H₂O and MeCN at 30° C. for 35 min. ₂

Example 3a: Synthesis of Di-Rhamnolipid Hexylamide

To activate the acid function, 25 g of di-rhamnolipid (40 mmol) with 6.25 ml of diisopropylcarbodiimide (40 mmol) are dissolved in THF at 55° C. If the mixture achieves an acid number of <2, 4.86 g of hexylamine (48 mmol) are added, and 1% by weight 4-dimethylamidopyridine for the catalysis. The resulting water of reaction promotes the formation of N,N'-diisopropylurea as secondary component. After a reaction time of 5 hours, the reaction mixture is dried on a rotary evaporator (45° C., <300 mbar), and is purified by shaking with ethyl acetate (1):water (1) (2×20 ml each time) in order to separate the resulting urea.

The ethyl acetate phase is evaporated (rotary evaporator, 45° C., <300 mbar) and the rhamnolipid hexylamide remains as a solid.

The product may be further purified by column chromatography. For this purpose, silica gel 60 (SIGMA Aldrich) as stationary phase and ethyl acetate (99):water (1) with 1% acetic acid serves as mobile phase. Hexylamine residues, polar by-products or possible cleavage products are removed from a 5% solution of the crude product. For careful 45 separation, a fraction comprises 10 ml at a dripping rate of 15 ml/min and a total volume of 200 ml starting solution.

Example 4: Description of the Application Effects and the Formulation

In order to evaluate the influence of the specified structures on the retention of fragrances on hair, an olfactory application test was carried out.

The hair bundle from Kerling used for the odour test were 55 prewashed firstly with a simple shampoo consisting of an aqueous solution of 12% sodium laureth sulphate, which has been adjusted to a viscosity of approx. 2500 mPas with sodium chloride, in accordance with the following procedure:

the hair bundles were wetted under running warm water. The excess water was gently squeezed by hand, then the shampoo was applied and gently worked into the hair (1 ml/hair tress (2 g)). After leaving on for 1 min, the hair was rinsed for 1 min. The prewashed, wet hair 65 bundles were then washed with the following shampoo formulations.

12

Formulations 1-3 and 7

5		Formu- lation 1 (according to the invention)	Formu- lation 2	Formu- lation 3	Formu- lation 7 (according to the invention)
10	Sorbitan	0.2%	0.2%	0.2%	0.2%
	Sesquicaprylate				
	Sodium Laureth	7.5%	7.5%	7.5%	7.5%
	Sulphate				
15	Geraniol	0.3%	0.3%		0.3%
10	Quatemium-80	1.0%	1.0%	1.0%	1.0%
15	Aqua/Water	ad 100%	ad 100%	ad 100%	ad 100%
	Cocamidopropyl	3.5%	3.5%	3.5%	3.5%
	Betaine				
20	PEG-18 Glyceryl	2.5%	2.5%	2.5%	2.5%
	Oleate/Cocoate				
	Glycol Distearate	1.0%	1.0%	1.0%	1.0%
	Rhamnolipid amide	3.0%			
25	according to Example 3				
25	Rhamnolipid amide				3.0%
	according to Example 3a				

Formulations 4-6 and 8:

5		Formu- lation 4 (according to the invention)	Formu- lation 5	Formu- lation 6	Formu- lation 8 (according to the invention)
	Sorbitan	0.2%	0.2%	0.2%	0.2%
	Sesquicaprylate				
	Sodium Laureth	6.5%	6.5%	6.5%	6.5%
0	Sulphate				
Ŭ	Citronellol	0.2%	0.2%		0.2%
	Quatemium-80	1.0%	1.0%	1.0%	1.0%
	Aqua/Water	ad 100%	ad 100%	ad 100%	ad 100%
	Cocamidopropyl	3.0%	3.0%	3.0%	3.0%
	Betaine				
5	PEG-18 Glyceryl	2.5%	2.5%	2.5%	2.5%
5	Oleate/Cocoate				
	Glycol Distearate	1.0%	1.0%	1.0%	1.0%
	Rhamnolipid amide	2.0%			
	according to Example 3				
	Rhamnolipid amide				2.0%
_	according to Example 3a				
()					

After drying for 24 hours in a climatically controlled room at 25° C. and 50% relative humidity, the olfactory impression of the hair was assessed by a trained panel consisting of 15 panellists according to the following scheme:

- 0 no fragrance-specific odour detectable
- 1 fragrance-specific odour just detectable
- 2 marked fragrance-specific odours detectable

The results of the olfactory assessment of the treatment, carried out as described above, of the hair bundles with formulations 1 and 4 and 7 according to the invention are compared with the results of comparison formulations 2 and 5 and also the control formulations 3 and 6 (placebo without fragrance) in the table below:

				13	
Results	from	the	Odour	Panel:	

Panel grade	Formu- lation 1 (according to the invention)	Formu- lation 2	Formu- lation 3	Formu- lation 7 (according to the invention)	4
after 24 h after 48 h after 96 h after 168 h	1.9 1.9 1.8 1.2	1.8 0.8 0.2 0.1	0.0 0.0 0.1 0.0	1.8 1.7 1.5 1.4	- 1
	Formu-			Formu- lation 8	-
Panel grade	lation 4 (according to the invention)	Formu- lation 5	Formu- lation 6	(according to the invention)	1

Surprisingly, the results of the odour panel test show that the hair treated with formulations 1 and 4 and 7 and 8 according to the invention have a significantly better fragrance retention than comparison formulations 2 and 5 and ²⁵ control formulations 3 and 6.

The invention claimed is:

1. A Rhamnolipid amide according the formula (I)

where m=2, 1 or 0,n=1 or 0

R¹=organic radical having 2 to 24 of carbon atoms, R²=independently of one another, identical or different, organic radical having 2 to 24, carbon atoms, R^{3a} =a structure selected from the group consisting of,

$$-R^6-N$$

$$R^5$$

14

wherein

R⁴ and R⁵=independently of one another, identical or different alkyl radical having 1 to 6 carbon atoms, R⁶=an alkylene group having 1 to 6 carbon atoms, and

$$-R^7$$

where

R⁷=an alkylene group having 1 to 22 carbon atoms, Z=H, OH, OR⁸ where

R⁸=alkyl radical having 1 to 6 carbon atoms, and R⁶=an alkylene group having 1 to 6 carbon atoms, and R^{3b}=hydrogen.

2. The rhamnolipid amide according to claim 1 wherein R⁴ and R⁵=independently of one another, identical or different alkyl radical having 1 to 3 carbon atoms,

R⁶=an alkylene group having 2 to 3 carbon atoms,

R⁷=an alkylene group having 2 to 18 carbon atoms, and R⁸=alkyl radical having 1 to 3 carbon atoms.

3. The rhamnolipid amide according to claim 1, wherein R⁶=an alkylene group having 1 to 3 carbon atoms, and R⁷=an alkylene group having 1 to 18 carbon atoms.

4. The rhamnolipid amide according to claim 1, wherein m=1 or 0,

n=1,

R¹=organic radical having 5 to 13 carbon atoms,

R²=independently of one another, identical or different, organic radical having 5 to 13 carbon atoms, and

 R^{3b} =organic radical having 4 to 8 carbon atoms or H.

5. The rhamnolipid amide according to claim 1, wherein m=1 or 0,

n=1,

R¹=organic radical selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and $(CH_2)_0$ — CH_3 where o=1 to 23,

R²=independently of one another, identical or different, organic radical having 2 to 24 selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and $(CH_2)_o$ — CH_3 where o=1 to 23, and $R^{3b}=H$.

6. The rhamnolipid amide according to claim **1**, wherein m=1 or 0,

n=1,

R¹=organic radical selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and $(CH_2)_o$ — CH_3 wherein o=4 to 12,

R²=independently of one another, identical or different, organic radical having 2 to 24 selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and $(CH_2)_o$ — CH_3 wherein o=4 to 12, and

 $R^{3b}=H$.

55

7. The rhamnolipid amide according to claim 1, wherein R⁴ and R⁵=independently of one another, identical or different alkyl radical having 1 carbon atom,

R⁶=an alkylene group having 2 to 3 carbon atoms,

R⁷=an alkylene group having 3 to 8 carbon atoms,

Z=H, OH, OR⁸ where

R⁸=alkyl radical having 1 carbon atoms, and $R^{3b}=H$.

8. A cosmetic formulation comprising the rhamnolipid

65 amide according to claim 1. 9. A hair fragrance comprising the rhamnolipid amide according to claim 8.

10. A process for the preparation of rhamnolipid amides comprising the process steps

A) providing a rhamnolipid,

B) reacting the rhamnolipid with at least one coupling reagent,

C) reacting the rhamnolipid activated by process step B) with an amine, and optionally

D) purifying out a rhamnolipid amide as set forth in claim 1.

11. The process according to claim 10, wherein in process step B) the coupling reagent is selected from the group consisting of dicyclohexylcarbodiimide, diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, N-cyclohexyl-N'-(2'-morpholinoethyl)carbodiimide metho-p-toluenesulphonate, N-benzyl-N'-3' dimethylaminopropylcarbodiimide hydrochloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, N-ethylcarbodiimide hydrochloride and carbonyldiimidazole.

12. The process according to claim 10, wherein in process step C) at least one catalyst selected from the the group consisting of N-ethyldiisopropylamine, trialkylamines, pyridine, 4-dimethylaminopyridine and hydroxybenzotriazole.

13. The process according to claim 10, wherein in process step B) the coupling reagent used is at least one selected from the group consisting of dicyclohexylcarbodiimide and diisopropylcarbodiimide.

14. The process according to claim 10, wherein in that in process step C) at least one catalyst is hydroxybenzotriazole.

15. The process according to claim 11, wherein in that in process step C) at least one catalyst is hydroxybenzotriazole.

16. A Rhamnolipid amide comprising the formula (I)

formula (I) $\begin{array}{c} R^{3a} \\ N \\ R^{3b}, \end{array}$ $\begin{array}{c} OH \\ OH \\ OH \\ OH \end{array}$ $\begin{array}{c} OH \\ OH \\ OH \\ OH \end{array}$

16

wherein

m=2, 1, or 0

n=1 or 0,

R¹ =organic radical having 2 to 24 carbon atoms,

R² =independently of one another, identical or different, organic radical having 2 to 24 carbon atoms,

 R^{3a} =a structure selected from the group consisting of

$$-R^6-N$$

$$R^4$$

$$R^5$$

wherein

R⁴ and R=independently of one another, identical or different alkyl radical having 1 to

6 carbon atoms,

R⁶=an alkylene group having 1 to 3 carbon atoms, and

$$-R^7$$

where

R⁷=an alkylene group having 1 to 22 carbon atoms, Z=H, OH, OR⁸ where

 R^8 =alkyl radical having 1 to 3 carbon atoms, and R^{ab} =hydrogen.

17. The rhamnolipid amide according to claim 16 wherein R⁴ and R⁵=independently of one another, identical or different alkyl radical having 1 to 3 carbon atoms,

R⁶=an alkylene group having 2 to 3 carbon atoms,

R⁷=an alkylene group having 2 to 18 carbon atoms.

18. The rhamnolipid amide according to claim 16, wherein

m=1 or 0,

n=1,

R¹=organic radical selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and (CH₂)o-CH₃ where o=1 to 23, and

R²=independently of one another, identical or different, organic radical having 2 to 24 selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and (CH₂)o-CH₃ where o=1 to 23.

19. The rhamnolipid amide according to claim 16, wherein

m=1 or 0,

n=1,

45

R¹=organic radical having 5 to 13 carbon atoms, and R²=independently of one another, identical or different, organic radical having 5 to 13 carbon atoms.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 10,941,173 B2

APPLICATION NO. : 16/074828

DATED : March 9, 2021

INVENTOR(S) : Xin Lu et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 16,

Line 16, Claim 16 " R^4 and R=independently" should read -- R^4 and R^5 = independently --.

Line 29, Claim 16 "Rab=hydrogen" should read -- R3b=hydrogen --.

Line 41, Claim 18 "and (CH₂)o-CH₃ where" should read -- and (CH₂)_o-CH₃ where --.

Line 45, Claim 18 "and (CH₂)o-CH₃ where" should read -- and (CH₂)_o-CH₃ where --.

Signed and Sealed this Thirteenth Day of April, 2021

Drew Hirshfeld

Performing the Functions and Duties of the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office